메뉴 건너뛰기




Volumn 120, Issue 14, 2014, Pages 2158-2163

Acute renal failure associated with the new BRAF inhibitor vemurafenib: A case series of 8 patients

Author keywords

acute renal failure; nephrotoxicity; renal insufficiency; side effect; vemurafenib

Indexed keywords

CARMUSTINE; CISPLATIN; CREATININE; DACARBAZINE; IODINATED CONTRAST MEDIUM; VEMURAFENIB; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE;

EID: 84903778501     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28709     Document Type: Article
Times cited : (55)

References (10)
  • 2
    • 84899892975 scopus 로고    scopus 로고
    • Survival according to BRAF-V600 tumor mutations: An analysis of 437 patients with primary melanoma
    • Meckbach D, Bauer J, Pflugfelder A, et al. Survival according to BRAF-V600 tumor mutations: An analysis of 437 patients with primary melanoma. PLoS One. 2014; 9: e86194.
    • (2014) PLoS One , vol.9
    • Meckbach, D.1    Bauer, J.2    Pflugfelder, A.3
  • 3
    • 84896714827 scopus 로고    scopus 로고
    • Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study
    • McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014; 15: 323-332.
    • (2014) Lancet Oncol , vol.15 , pp. 323-332
    • McArthur, G.A.1    Chapman, P.B.2    Robert, C.3
  • 5
    • 79959795786 scopus 로고    scopus 로고
    • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: 2507-2516.
    • (2011) N Engl J Med , vol.364 , pp. 2507-2516
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3
  • 6
    • 79960720836 scopus 로고    scopus 로고
    • ZELBORAF® (Vemurafenib) tablet for oral use Nutley, NJ: Hoffmann-La Roche; initial US approval 2011; revised March 2014
    • ZELBORAF® (Vemurafenib) tablet for oral use. Highlights of prescribing information. Nutley, NJ: Hoffmann-La Roche; initial US approval 2011; revised March 2014; http://www.gene.com/download/pdf/zelboraf-prescribing. pdf.
    • Highlights of Prescribing Information
  • 7
    • 84872220501 scopus 로고    scopus 로고
    • US Food and Drug Administration Revised August
    • US Food and Drug Administration. Zelboraf. Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 202429s000lbl.pdf. Revised August 2011.
    • (2011) Zelboraf. Highlights of Prescribing Information
  • 8
    • 84903784475 scopus 로고    scopus 로고
    • Dictionnaire Vidal. RO5185426 (VEMURAFENIB) 240 mg cp pellic. [in French]. Updated February 20, 2014
    • Dictionnaire Vidal. RO5185426 (VEMURAFENIB) 240 mg cp pellic. 2013; http://www.vidal.fr/Medicament/ro5185426-vemurafenib-107154.htm [in French]. Updated February 20, 2014.
    • (2013)
  • 10
    • 84903788238 scopus 로고    scopus 로고
    • Réactions graves d'hypersensibilité avec insuffisance rénale après exposition solaire sous vemurafenib [in French]
    • Regnier-Rosencher E, Gressier L, Avril M-F, Dupin N,. Réactions graves d'hypersensibilité avec insuffisance rénale après exposition solaire sous vemurafenib [in French]. Ann Dermatol Venereol. 2012; 139: B92.
    • (2012) Ann Dermatol Venereol , vol.139
    • Regnier-Rosencher, E.1    Gressier, L.2    Avril, M.-F.3    Dupin, N.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.